Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells $138,518.38 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 5,698 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the transaction, the chief executive officer now directly owns 1,496,729 shares in the company, valued at approximately $36,385,481.99. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $24.36 on Monday. The company’s 50-day simple moving average is $21.29 and its 200-day simple moving average is $18.72. Tyra Biosciences, Inc. has a 1 year low of $10.38 and a 1 year high of $25.14. The stock has a market capitalization of $1.28 billion, a PE ratio of -14.50 and a beta of 1.01.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. On average, sell-side analysts predict that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TYRA shares. Piper Sandler assumed coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Finally, Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $26.40.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently modified their holdings of the company. RA Capital Management L.P. grew its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL lifted its stake in Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after purchasing an additional 1,921,599 shares during the last quarter. Kynam Capital Management LP acquired a new position in Tyra Biosciences in the fourth quarter valued at approximately $4,712,000. Perceptive Advisors LLC increased its stake in Tyra Biosciences by 50.5% in the second quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after purchasing an additional 338,208 shares during the last quarter. Finally, Ally Bridge Group NY LLC acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $4,232,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.